Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Chart School
Tutorials
Learning Center
Glossary
Submit Article
Join Blog Network
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Microbix to Present at Rodman & Renshaw Investor Healthcare Conference. Management to Highlight Pipeline Opportunities.
Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
Microbix Announces A New Technology Platform For The SST Project
Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
Microbix Extends Expiry Date of Share Purchase Warrants
Microbix Enters The Urokinase Market
Microbix Continues Progress in Implementing Strategic Plan in Q3
Microbix Enters into Joint Venture in China to Build and Operate One of the Largest Influenza Vaccine Manufacturing Facilities in the World
Microbix and ImaRx Agree to Terminate Letter of Intent
ImaRx Therapeutics and Microbix Biosystems Terminate Letter of Intent for Sale of Urokinase
Microbix VIRUSMAX(TM) Technology Continues to Attract Interest from Vaccine Manufacturers
Reporters/Editors: ^China grants patent protection to Microbix for its influenza vaccine yield enhancement technology
Microbix Makes Significant Progress in Implementing Strategic Plan in Q2
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
